The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Roy Castle Lung Cancer: genomics and novel risk models
John Field, MA, PhD, BDS, FRCPath, University of Liverpool, Liverpool, UK, shares an update on Roy Castle Lung Cancer research projects, including the Liverpool Lung Project which has developed and expanded the LLP risk model. Prof. Field outlines the use of the LLP risk model as well as genome-wide association studies (GWAS) looking at susceptibility genes, the discovery of molecular biomarkers, radiomics and novel risk models. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
Disclosures
Prof. John Field, MA, PhD, BDS, FRCPath, has participated in a speaker’s bureau with AstraZeneca; has participated in advisory boards for Epigenomics, NUCLEIX Ltd., AstraZeneca and iDNA; and has received grant support from Janssen Research & Development, LLC.
